MHRA approves olaparib for high-risk, early-stage breast cancer 07 Sep 2022 The Institute of Cancer Research, London, celebrates the news that the precision medicine olaparib has been approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), for patients with high-risk, early-stage breast cancer and inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
ICR criticises NICE rejection of olaparib for advanced prostate cancer 06 Sep 2022 The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer. Find out more Show/Hide
Olaparib for high-risk, early-stage breast cancer approved in Europe 04 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that the precision medicine olaparib has been approved in Europe for people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022
ESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022
ASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021